Default company panoramic image
Afa1efed 2a68 4c3f b692 50c479c94c78

Companion Diagnostics

CDI develops and markets stabilizers that improve shelf life and performance of diagnostics, nutraceuticals, dietary supplements, and foods.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Founded January 2009
  • Employees 4
  • Website

Company Summary

In the global economy enhanced shelf life is increasingly important, as is the need to replace chemicals with natural clean ingredients. Companion Diagnostics (CDI) replaces low performance reagents with high performance clean label Proprietary Stabilizing Products (PSPs) that are easily incorporated into customer's in vitro diagnostics, supplements, nutraceuticals, and foods. Customers include diagnostic firms Alere, Bio-Rad, Quidel and others.


  • Default avatar
    Richard Selinfreund

    30 patents granted; more than $5MM in IP license fees
    PhD Los Alamos; former research scientist Yale University

  • Default avatar
    Robert Martinsons

    Nanogen ($80MM IPO)
    Founded two business units of Motorola ($300MM revenue)
    Extensive startup consulting experience

  • Default avatar
    Mark Germain

    Co founder Neurocrine (NASD: NBIX $500MM), Incyte (NASD: INCY $2.5B), Ariad (NASD: ARIA $3.95B), Alexion (NASD: ALXN $22B)


  • Default avatar
    Mitch Goldsmith Shefsky & Froelich